0001493152-23-024172.txt : 20230711 0001493152-23-024172.hdr.sgml : 20230711 20230711085535 ACCESSION NUMBER: 0001493152-23-024172 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20230707 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230711 DATE AS OF CHANGE: 20230711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jupiter Wellness, Inc. CENTRAL INDEX KEY: 0001760903 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 832455880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39569 FILM NUMBER: 231081268 BUSINESS ADDRESS: STREET 1: 1061 E. INDIANTOWN RD. STREET 2: STE. 110 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: 561-325-0482 MAIL ADDRESS: STREET 1: 1061 E. INDIANTOWN RD. STREET 2: STE. 110 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: CBD Brands, Inc. DATE OF NAME CHANGE: 20181206 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C., 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2023

JUPITER WELLNESS, INC.

(Exact name of registrant as specified in charter)

Delaware

001-39569

83-2455880

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1061 E. Indiantown Rd., Ste. 110, Jupiter, FL 33477

(Address of principal executive offices) (Zip Code)

(561) 462-2700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		JUPW		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Warrants, each exercisable for one share of Common Stock at $8.50 per share		JUPWW		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 7, 2023, the board of directors (the “Board”) of Jupiter Wellness, Inc. (the “Company”) appointed David Sandler as the Chief Operating Officer of the Company for a guaranteed two-year term with auto extension/renewal.

David Sandler, Chief Operating Officer, is a goal-driven executive with more than 30 years experience in the nutrition and health industry developing, building and managing high-growth, results-oriented projects. David is the founder of StrengthPro Inc., a consulting firm specializing specific areas of health, fitness, nutrition, and supplement ratio. David has been working as the president of Strengthpro since January 2021. Since May 2019 David has been serving as chief operations officer at Elite Beverage. From October 2016 to October 2019, David served as the chief operations officer at ProSupps USA, LLC.

In connection with his employment as the Chief Operating Officer, the Company entered into an employment agreement with David (the “David Agreement”). Pursuant to the David Agreement, David is entitled to:

	●	Compensation: $150,000 per-annum, paid bi-monthly, which may be increased at the sole discretion of the Company and based on David’s performance.
	●	Bonus: annual bonus based on meeting the pre-determined target.
	●	Miscellaneous: cost of living adjustment, paid vacation, paid holidays, and business expense and cell phone reimbursement.
	●	Stock Options: 100 shares of common stock, subject to the terms and conditions of the Agreement.

On July 7, 2023, the Board appointed Josh Wagner as the Chief Revenue Officer of the Company for a guaranteed two-year term with auto extension/renewal.

Josh Wagner, Chief Revenue Officer, is the founder of Limitless Agency, a a consulting agency specializing in beverage industry. From December 2019 to May 2023, he served as the Strategy & Growth Consultant at Lyrical Lemonade where he developed beverage strategy including short/medium/long term planning, incubation, operations, sales and commercial integration. Josh worked as the Director of Sales at Anheuser-Busch InBev from December 2017 to December 2019. Josh has a Bachelor of Science, Business Administration degree from University of Missouri.

In connection with his employment as the Chief Revenue Officer, the Company entered into an employment agreement with Josh (the “Josh Agreement” along with the David agreement as the “Employment Agreements”). Pursuant to the Josh Agreement, Josh is entitled to:

	●	Compensation: $150,000 per-annum, paid bi-monthly, which may be increased at the sole discretion of the Company and based on David’s performance.
	●	Bonus: annual bonus based on meeting the pre-determined target.
	●	Miscellaneous: cost of living adjustment, paid vacation, paid holidays, and business expense and cell phone reimbursement.
	●	Stock Options: 100 shares of common stock, subject to the terms and conditions of the Agreement.

The foregoing description of each of the Employment Agreements does not purport to be complete and are qualified in their entirety by the text of the Employment Agreements which are filed as Exhibit 10.1 and Exhibit 10.2 hereto, respectively, and are incorporated herein by reference.

There are no arrangements or understandings between the Company and the newly appointed executive officer or director and any other person or persons pursuant to which each executive officer or director was appointed and there is no family relationship between or among any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.

There are no transactions between the Company and any newly appointed executive officer or director that are reportable pursuant to Item 404(a) of Regulation SK. The Company did not enter into or materially amend any material plan, contract or arrangement with any newly appointed executive officer or director in connection with his or her appointment as a director or executive officer.

Item 7.01 Regulation FD Disclosure.

On July 10, 2023, the Company issued a press release announcing the Company entering into the Employment Agreements, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

Exhibits

Exhibit No.		Description
10.1		Form of Employment Agreement dated July 10, 2023, by and between the Company and David Sandler
10.2		Form of Employment Agreement dated July 10, 2023, by and between the Company and Josh Wagner
99.1		Press Release dated July 11, 2023
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 11, 2023

	JUPITER WELLNESS, INC.

	By:	/s/ Brian John
		Brian John
		Chief Executive Officer

EX-10.2 2 ex10-1.htm

Exhibit 10.1

JUPITER WELLNESS, INC
EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of July 10^th, 2023, (the “Effective Date”), between Jupiter Wellness Inc., a Delaware corporation, whose principal place of business is 1061 E Indiantown Rd, Suite 110, Jupiter, FL 33477 (the “Company”, or “Employer”) and David Sandler, an individual whose mailing address is 2314 S Holman Circle, Lakewood CO 80228, (the “Employee”).

RECITALS

WHEREAS, the Company desires to employ the Employee and the Employee desires to be employed by the Company and to enter into a formal employment agreement for the benefit and protection of all parties.

NOW, THEREFORE, in consideration of the mutual agreements herein made, the Company and the Employee do hereby agree as follows:

	1.	Recitals. The above recitals are true, and correct, and are herein incorporated by reference.

	2.	Employment. The Company hereby employs the Employee, and the Employee hereby accepts employment, upon the terms and conditions hereinafter set forth.

	3.	Duties and Responsibilities. During the term of this Agreement, the Employee shall serve as Chief Operating Officer of the Company. The Employee shall report to the CEO.

	4.	Term. The term of employment hereunder will commence on July 10^th, 2023, and continue for a period of two (2) years, which shall auto-renew for successive one (1) year periods unless terminated in accordance herewith (collectively the “Term”).

	5.	Compensation and Benefits.

	a.	Salary. During the Term of this Agreement, the Employee shall be paid an initial base salary (the “Base Salary”) paid twice monthly, at an annualized rate of One Hundred Fifty Thousand dollars ($150,000).

	b.	Bonus. The Company shall pay the Employee an annual bonus (the “Bonus”) based on targets (the “Bonus Targets”) set forth below and established by mutual agreement. The Bonus amount shall be set as To Be Determined. Upon each subsequent year’s anniversary of employment, new Bonus Targets shall be established.

		i.	Bonus Targets. To Be Determined

c.

Pay Increase. The Employee’s base salary may be increased at any time, at the Company’s sole discretion, based on the Employee’s performance, contributions to the Company, and other factors deemed relevant by the Employer. Any such increase shall be communicated to the Employee in writing and shall take effect on a date determined by the Employer.

	d.	Cost of Living Adjustment. The Employee’s base salary shall be subject to an annual Cost of Living Adjustment (the “COLA”) based on the Consumer Price Index (CPI) for All Urban Consumers (CPI-U) for the previous year. The COLA shall be calculated as a percentage increase and shall take effect on the first day of each calendar year.

	e.	Stock Options. Under this Agreement, the Employee’s compensation may include either stock options or restricted stock. Specific details about the issuance of these equity awards, such as the grant date, vesting schedule, and strike price, will be available in Appendix A. Please refer to this appendix and the 2022 Omnibus Equity Incentive Plan for more information.

	f.	Benefits. Upon signing this Agreement, the Employee becomes eligible for mandatory employee benefits required by law and other benefits the Company may offer. Benefits may include health, life, and disability insurance coverage, a 401(k) plan, and an Employee Stock Ownership Plan. The Company can update or modify its offerings at any time, and the Employee will be notified of any changes. For more information, refer to the Jupiter Wellness Employee Handbook.

	g.	Vacation. The Company offers its employees two different time-off plans: Paid Time Off (PTO) and Responsible Time Off (RTO). The RTO plan is offered to benefit-eligible exempt employees in the United States, while the accrued PTO plan is offered to non-exempt (hourly) employees in the United States. Please refer to the Jupiter Wellness Employee Handbook for specific details on each plan, including eligibility criteria and accrual rates. We are committed to providing our employees with comprehensive and competitive benefits packages, including generous time off policies, to support their well-being and work-life balance.

	h.	Holidays. The Company shall provide the Employee with a certain number of paid holidays each calendar year, as determined by the U.S. federal holidays designated by Congress. While the specific observance dates may change from year to year, all Federal bank and market holidays shall be observed by the Company as paid vacation days.

	i.	Business Expense Reimbursement. During the term of employment, the Employee shall be entitled to receive proper reimbursement for all reasonable, out-of-pocket expenses incurred by the Employee (in accordance with the policies and procedures established by the Company for its employees) in performing services hereunder, provided the Employee properly accounts therefor.

	j.	Cell Phone Usage Reimbursement. The Employee will receive a $125 monthly stipend for business use of their personal cell phone. The stipend doesn’t cover the device cost or the full monthly bill. To qualify, the Employee must agree to the Bring Your Own Device Policy. This policy covers data protection, security, and acceptable use. By accepting the stipend, the Employee agrees to comply with the policy and use their phone in line with company standards.

6.

Consequences of Termination of Employment.

a.

Death. This Agreement and the Employee’s employment hereunder shall be terminated by the death of the Employee and all vested but unexercised Options shall remain exercisable by the Employee’s designated beneficiary, or, in the absence of such designation, to the estate or other legal representative of the Employee, through the term of such Option.

	b.	Disability. In the event of the Employee’s disability, as hereinafter defined, the Employee shall be entitled to compensation in accordance with the Company’s disability compensation practice for Employees.

	c.	Termination by the Company for Cause.

	i.	Nothing herein shall prevent the Company from terminating Employment for “Cause,” as hereinafter defined. The Employee shall continue to receive the Base Salary through the date of such termination and any vested Stock Options shall remain exercisable pursuant to the terms of such grants.

	ii.	“Cause” shall mean and include those actions or events specified below in subsections (A) through (D) to the extent the same occur, or the events constituting the same take place, subsequent to the date of execution of this Agreement: (A) committing or participating in an injurious act of, gross neglect or embezzlement against the Company; (B) committing or participating in any other injurious act or omission wantonly, willfully, recklessly or in a manner which was grossly negligent against the Company, monetarily or otherwise; (C) engaging in a criminal enterprise involving moral turpitude; or (D) the Employee being charged with or a conviction of an act or acts constituting a felony under the laws of the United States or any state thereof. Any other termination shall be deemed a termination “Other than for Cause.”

	d.	Termination by the Company Other than for Cause. The foregoing notwithstanding, the Company may terminate the Employee’s employment for whatever reason it deems appropriate: On the date of termination, the Employee’s unexercised vested Stock Options shall remain exercisable by the Employee through the term of such Options. On the date of termination, the Company shall pay to Employee the following benefits at the times specified below: (A) all Earned Compensation (to be paid on the date of termination), (B) an amount equal to all accrued and unpaid annual incentive bonuses relating to any prior years, if any, at the time of Employee’s termination of employment, (C) all Reimbursable Expenses, and, (D) a pro-rata portion of any annual incentive bonus becoming earned on performance for the fiscal year in which the date of termination occurs.

	e.	Voluntary Termination. In the event, the Employee terminates the Employee’s employment of the Employee’s own volition, on the date of termination the Employee’s unexercised vested Stock Options shall remain exercisable by the Employee through the term of such Options.

7.

Restrictive Covenant and Non-Disclosure of Information.

	a.	Restrictive Covenant. The Employee acknowledges and recognizes the highly competitive nature of the Company’s business and the goodwill, continued patronage, and specifically the names and addresses of the Company’s Clients (as hereinafter defined) constitute a substantial asset of the Company having been acquired through considerable time, money, and effort. Accordingly, in consideration of the execution of this Agreement, in the event the Employee’s employment is terminated by reason of disability pursuant to Section 6(b) or for Cause pursuant to Section 6(c) or if the Employee voluntarily terminates this Agreement pursuant to Section 6(e), then the Employee agrees that during the Restricted Period and within the Restricted Area, the Employee will not, directly or indirectly, solicit, induce or influence any of the Company’s Clients which have a business relationship with the Company at the time during the Restricted Period to discontinue or reduce the extent of such relationship with the Company and shall not solicit any current employee of the Company to offer them employment away from the Company.

	b.	Non-Disclosure of Information. In the event Employee’s employment has been terminated, Employee agrees that, during the Restricted Period, Employee will not knowingly use or disclose any Proprietary Information of the Company for the Employee’s own purposes or for the benefit of any entity engaged in Competitive Business Activities. As used herein, the term “Proprietary Information” shall mean trade secrets or confidential proprietary information of the Company which are material to the conduct of the business of the Company. No information can be considered Proprietary Information unless the same is a unique process or method material to the conduct of the Company’s business, or is a customer list or similar list of persons engaged in business activities with the Company, or if the same is otherwise in the public domain or is required to be disclosed by order of any court or by reason of any statute, law, rule, regulation, ordinance or other governmental requirements. Employee further agrees that in the event his employment is terminated all Documents in his possession at the time of his termination shall be returned to the Company at the Company’s principal place of business.

	c.	Documents. “Documents” shall mean all original written, recorded, or graphic matters whatsoever, and any and all copies thereof, including, but not limited to: papers; books; records; tangible things; correspondence; communications; telex messages; memoranda; work papers; reports; affidavits; statements; summaries; analyses; evaluations; client records and information; agreements; agendas; advertisements; instructions; charges; manuals; brochures; publications; directories; industry lists; schedules; price lists; client lists; statistical records; training manuals; computer printouts; books of account, records and invoices reflecting business operations; all things similar to any of the foregoing however denominated. In all cases where originals are not available, the term “Documents” shall also mean identical copies of original documents or non-identical copies thereof.

	d.	Company’s Clients. The “Company’s Clients” shall be deemed to be any partnerships, corporations, professional associations or other business organizations with whom the Company has conducted business.

	e.	Restrictive Period. The “Restrictive Period” shall be deemed to be five (5) years following termination of the Employee’s employment with the Company.

	f.	Restricted Area. The “Restricted Area” shall be within a three hundred (300) mile radius of the Company’s principal office at the time of termination.

	g.	Competitive Business Activities. The term “Competitive Business Activities” as used herein shall be deemed to mean the business of the Company at the time of termination.

	h.	Covenants as Essential Elements of this Agreement. It is understood by and between the parties hereto that the foregoing covenants contained in Sections 7(a) and (b) are essential elements of this Agreement, and that but for the agreement by the Employee to comply with such covenants, the Company would not have agreed to enter into this Agreement. Such covenants by the Employee shall be construed to be agreements independent of any other provisions of this Agreement. The existence of any other claim or cause of action, whether predicated on any other provision in this Agreement, or otherwise, because of the relationship between the parties shall not constitute a defense to the enforcement of such covenants against the Employee.

	i.	Survival After Termination of Agreement. Notwithstanding anything to the contrary contained in this Agreement, the covenants in Sections 7(a) and (b) shall survive the termination of this Agreement and the Employee’s employment with the Company.

	j.	Remedies.

	i.	The Employee acknowledges and agrees that the Company’s remedy at law for a breach or threatened breach of any of the provisions of Section 7(a) or (b) herein would be inadequate and a breach thereof will cause irreparable harm to the Company. In recognition of this fact, in the event of a breach by the Employee of any of the provisions of Section 7(a) or (b), the Employee agrees that, in addition to any remedy at law available to the Company, including, but not limited to monetary damages, all rights of the Employee to payment or otherwise under this Agreement and all amounts then or thereafter due to the Employee from the Company under this Agreement may be terminated and the Company, without posting any bond, shall be entitled to obtain, and the Employee agrees not to oppose the Company’s request for equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available to the Company.

	ii.	The Employee acknowledges that the granting of a temporary injunction, temporary restraining order, or permanent injunction merely prohibiting the use of Proprietary Information would not be an adequate remedy upon breach or threatened breach of Section 7(a) or (b) and consequently agrees, upon proof of any such breach, to the granting of injunctive relief prohibiting any form of competition with the Company. Nothing contained herein shall be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened breach.

8.

Indemnification. The Employee shall continue to be covered by the Certificate of Incorporation and/or the Bylaws of the Company with respect to matters occurring on or prior to the date of termination of the Employee’s employment with the Company, subject to all the provisions of Delaware and Federal law and the Certificate of Incorporation and Bylaws of the Company then in effect. Such reasonable expenses, including attorneys’ fees, that may be covered by the Certificate of Incorporation and/or Bylaws of the Company shall be paid by the Company on a current basis in accordance with such provision, the Company’s Certificate of Incorporation, and Delaware law. To the extent that any such payments by the Company pursuant to the Company’s Certificate of Incorporation and/or Bylaws may be subject to repayment by the Employee pursuant to the provisions of the Company’s Certificate of Incorporation or Bylaws, or pursuant to Delaware or Federal law, such repayment shall be due and payable by the Employee to the Company within three (3) months after the termination of all proceedings, if any, which relate to such repayment and to the Company’s affairs for the period prior to the date of termination of the Employee’s employment with the Company and as to which Employee has been covered by such applicable provisions.

	9.	Background. Jupiter Wellness understands the importance of creating a safe and secure work environment for all employees. As such, the Company reserves the right to conduct background investigations and/or reference checks on all potential employees. Please note that any job offer extended by the Company is contingent upon the successful completion of such checks.

	10.	Policies. Jupiter Wellness employees are expected to follow the company’s rules and standards to create a safe and respectful workplace for everyone. To ensure compliance with these standards, employees will receive a copy of the Jupiter Wellness Employee Handbook, along with other relevant company policies, such as Regulation FD and Insider Trading Policies. The employee acknowledges that the terms of this contract are subject to and incorporate the policies and procedures set forth in the company’s employee handbook and any other applicable policies, which the employee agrees to review and abide by. The contract will not become effective until the employee signs and acknowledges receipt of the employee handbook and any other applicable policies.

	11.	Withholding. Anything to the contrary notwithstanding, all payments required to be made by the Company hereunder to the Employee or the Employee’s estate or beneficiaries shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as the Company may reasonably determine it should withhold pursuant to any applicable law or regulation. In lieu of withholding such amounts, the Company may accept other arrangements pursuant to which it is satisfied that such tax and other payroll obligations will be satisfied in a manner complying with applicable law or regulation.

	12.	Notices. Any notice required or permitted to be given under the terms of this Agreement shall be sufficient if in writing and if sent postage prepaid by registered or certified mail, return receipt requested; by overnight delivery; by courier; or by confirmed telecopy, in the case of the Employee to the Employee’s last place of business or residence as shown on the records of the Company, or in the case of the Company to its principal office as set forth in the first paragraph of this Agreement, or at such other place as it may designate.

	13.	Waiver. Unless agreed in writing, the failure of either party, at any time, to require performance by the other of any provisions hereunder shall not affect its right thereafter to enforce the same, nor shall a waiver by either party of any breach of any provision hereof be taken or held to be a waiver of any other preceding or succeeding breach of any term or provision of this Agreement. No extension of time for the performance of any obligation or act shall be deemed to be an extension of time for the performance of any other obligation or act hereunder.

	14.	Completeness and Modification. This Agreement constitutes the entire understanding between the parties hereto superseding all prior and contemporaneous agreements or understandings among the parties hereto concerning the Employment Agreement. This Agreement may be amended, modified, superseded, or canceled, and any of the terms, covenants, representations, warranties, or conditions hereof may be waived, only by a written instrument executed by the parties or, in the case of a waiver, by the party to be charged.

	15.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute but one agreement.

	16.	Binding Effect/Assignment. This Agreement shall be binding upon the parties hereto, their heirs, legal representatives, successors, and assigns. This Agreement shall not be assignable by the Employee but shall be assignable by the Company in connection with the sale, transfer, or other disposition of its business or to any of the Company’s affiliates controlled by or under common control with the Company.

	17.	Governing Law. This Agreement shall become valid when executed and accepted by Company. The parties agree that it shall be deemed made and entered into in the State of Florida and shall be governed and construed under and in accordance with the laws of the State of Florida. Anything in this Agreement to the contrary notwithstanding, the Employee shall conduct the Employee’s business in a lawful manner and faithfully comply with applicable laws or regulations of the state, city, or other political subdivision in which the Employee is located.

	18.	Further Assurances. All parties hereto shall execute and deliver such other instruments and do such other acts as may be necessary to carry out the intent and purposes of this Agreement.

	19.	Headings. The headings of the sections are for convenience only and shall not control or affect the meaning or construction or limit the scope or intent of any of the provisions of this Agreement.

	20.	Survival. Any termination of this Agreement shall not, however, affect the ongoing provisions of this Agreement which shall survive such termination in accordance with their terms.

	21.	Severability. The invalidity or unenforceability, in whole or in part, of any covenant, promise or undertaking, or any section, subsection, paragraph, sentence, clause, phrase, or word or of any provision of this Agreement shall not affect the validity or enforceability of the remaining portions thereof.

	22.	Enforcement. Should it become necessary for any party to institute legal action to enforce the terms and conditions of this Agreement, the successful party will be awarded reasonable attorney’s fees at all trial and appellate levels, expenses, and costs.

	23.	Venue. The Company and the Executive acknowledge and agree that the 15^th Judicial Circuit of Florida shall be the venue and exclusive proper forum in which to adjudicate any case or controversy arising either, directly or indirectly, under or in connection with this Agreement and the parties further agree that, in the event of litigation arising out of or in connection with this Agreement in these courts, they will not contest or challenge the jurisdiction or venue of these courts.

	24.	Construction. This Agreement shall be construed within the fair meaning of each of its terms and not against the party drafting the document.

	25.	Superseding Agreement. This Agreement supersedes all prior or contemporaneous agreements, whether written or oral, and constitutes the entire understanding between the parties. Any changes to this Agreement must be in writing and signed by both parties. If there is any conflict between this Agreement and any other document or agreement related to the subject matter, this Agreement shall prevail.

	26.	Approval of Named Officers. Notwithstanding any provision to the contrary, any compensation, incentive, or benefit arrangement for Named Officers of the company shall be deemed effective only upon the express approval of the Board of Directors, following a recommendation from the Compensation Committee.

IN WITNESS WHEREOF, the parties have executed this Agreement as of date set forth in the first paragraph of this Agreement.

	THE COMPANY

	JUPITER WELLNESS, INC.

	By:	/s/
		Brian John, CEO

	THE EMPLOYEE

		/s/

APPENDIX A
EQUITY COMPENSATION DETAILS

This appendix contains additional information about the Employee’s compensation through the issuance of either stock options or restricted stock. Please refer to this appendix for a detailed description of the grant date, vesting schedule, and strike price for these equity awards.

Jupiter Wellness, Inc. hereby grants the Employee stock options to purchase up to 100,000 shares of our common stock (the “Stock Options”). These Stock Options are subject to the terms and conditions set forth in the Company’s 2022 Omnibus Equity Incentive Plan (the “Plan”).

Covered Shares:		100,000 shares of common stock, par value $0.001 per share.

Date of Grant:		The “Date of Grant” for the Stock Options is July 10^th, 2023.

Exercise Price:		The purchase price for these shares will be the closing market price of the Company’s stock on the Date of Grant.

Vesting Schedule:		You may exercise your Stock Options after they become “vested.” Vesting is subject to continued employment with Jupiter Wellness, Inc. after the Date of the Grant.

Vesting Date		Number of Purchasable Shares		Total Number of Purchasable Shares
July 10, 2023		8337		8337
October 10, 2023		8333		16670
January 10, 2024		8333		25003
April 10, 2024		8333		33336
July 10, 2024		8333		41669
October 10, 2024		8333		50002
January 10, 2025		8333		58335
April 10, 2025		8333		66668
July 10, 2025		8333		75001
October 10, 2025		8333		83334
January 10, 2026		8333		91667
April 10, 2026		8333		100000

Termination:		Subject to the terms of the Plan, the vested portion of the Stock Options will remain exercisable for 90 days after the date of employment termination.

ISOs:		These Stock Options are “incentive stock options” under federal tax laws.

Expiration Date:		If not previously exercised or forfeited, the Stock Options expire on July 10^th, 2028.

EX-10.3 3 ex10-2.htm

Exhibit 10.2

JUPITER WELLNESS, INC
EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of July 10^th, 2023, (the “Effective Date”), between Jupiter Wellness Inc., a Delaware corporation, whose principal place of business is 1061 E Indiantown Rd, Suite 110, Jupiter, FL 33477 (the “Company”, or “Employer”) and Josh Wagner, an individual whose mailing address is 210 Parkside Ln., Oswego, IL 60543 (the “Employee”).

RECITALS

WHEREAS, the Company desires to employ the Employee and the Employee desires to be employed by the Company and to enter into a formal employment agreement for the benefit and protection of all parties.

NOW, THEREFORE, in consideration of the mutual agreements herein made, the Company and the Employee do hereby agree as follows:

	1.	Recitals. The above recitals are true, and correct, and are herein incorporated by reference.

	2.	Employment. The Company hereby employs the Employee, and the Employee hereby accepts employment, upon the terms and conditions hereinafter set forth.

	3.	Duties and Responsibilities. During the term of this Agreement, the Employee shall serve as Chief Revenue Officer of the Company. The Employee shall report to the CEO.

	4.	Term. The term of employment hereunder will commence on July 10^th, 2023, and continue for a period of two (2) years, which shall auto-renew for successive one (1) year periods unless terminated in accordance herewith (collectively the “Term”).

	5.	Compensation and Benefits.

		a.	Salary. During the Term of this Agreement, the Employee shall be paid an initial base salary (the “Base Salary”) paid twice monthly, at an annualized rate of One Hundred Fifty Thousand dollars ($150,000).

		b.	Bonus. The Company shall pay the Employee an annual bonus (the “Bonus”) based on targets (the “Bonus Targets”) set forth below and established by mutual agreement. The Bonus amount shall be set as To Be Determined. Upon each subsequent year’s anniversary of employment, new Bonus Targets shall be established.

i.

Bonus Targets. To Be Determined

c.

Pay Increase. The Employee’s base salary may be increased at any time, at the Company’s sole discretion, based on the Employee’s performance, contributions to the Company, and other factors deemed relevant by the Employer. Any such increase shall be communicated to the Employee in writing and shall take effect on a date determined by the Employer.

		d.	Cost of Living Adjustment. The Employee’s base salary shall be subject to an annual Cost of Living Adjustment (the “COLA”) based on the Consumer Price Index (CPI) for All Urban Consumers (CPI-U) for the previous year. The COLA shall be calculated as a percentage increase and shall take effect on the first day of each calendar year.

		e.	Stock Options. Under this Agreement, the Employee’s compensation may include either stock options or restricted stock. Specific details about the issuance of these equity awards, such as the grant date, vesting schedule, and strike price, will be available in Appendix A. Please refer to this appendix and the 2022 Omnibus Equity Incentive Plan for more information.

		f.	Benefits. Upon signing this Agreement, the Employee becomes eligible for mandatory employee benefits required by law and other benefits the Company may offer. Benefits may include health, life, and disability insurance coverage, a 401(k) plan, and an Employee Stock Ownership Plan. The Company can update or modify its offerings at any time, and the Employee will be notified of any changes. For more information, refer to the Jupiter Wellness Employee Handbook.

		g.	Vacation. The Company offers its employees two different time-off plans: Paid Time Off (PTO) and Responsible Time Off (RTO). The RTO plan is offered to benefit-eligible exempt employees in the United States, while the accrued PTO plan is offered to non-exempt (hourly) employees in the United States. Please refer to the Jupiter Wellness Employee Handbook for specific details on each plan, including eligibility criteria and accrual rates. We are committed to providing our employees with comprehensive and competitive benefits packages, including generous time off policies, to support their well-being and work-life balance.

		h.	Holidays. The Company shall provide the Employee with a certain number of paid holidays each calendar year, as determined by the U.S. federal holidays designated by Congress. While the specific observance dates may change from year to year, all Federal bank and market holidays shall be observed by the Company as paid vacation days.

		i.	Business Expense Reimbursement. During the term of employment, the Employee shall be entitled to receive proper reimbursement for all reasonable, out-of-pocket expenses incurred by the Employee (in accordance with the policies and procedures established by the Company for its employees) in performing services hereunder, provided the Employee properly accounts therefor.

		j.	Cell Phone Usage Reimbursement. The Employee will receive a $125 monthly stipend for business use of their personal cell phone. The stipend doesn’t cover the device cost or the full monthly bill. To qualify, the Employee must agree to the Bring Your Own Device Policy. This policy covers data protection, security, and acceptable use. By accepting the stipend, the Employee agrees to comply with the policy and use their phone in line with company standards.

6.

Consequences of Termination of Employment.

a.

Death. This Agreement and the Employee’s employment hereunder shall be terminated by the death of the Employee and all vested but unexercised Options shall remain exercisable by the Employee’s designated beneficiary, or, in the absence of such designation, to the estate or other legal representative of the Employee, through the term of such Option.

		b.	Disability. In the event of the Employee’s disability, as hereinafter defined, the Employee shall be entitled to compensation in accordance with the Company’s disability compensation practice for Employees.

		c.	Termination by the Company for Cause.

		i.	Nothing herein shall prevent the Company from terminating Employment for “Cause,” as hereinafter defined. The Employee shall continue to receive the Base Salary through the date of such termination and any vested Stock Options shall remain exercisable pursuant to the terms of such grants.

		ii.	“Cause” shall mean and include those actions or events specified below in subsections (A) through (D) to the extent the same occur, or the events constituting the same take place, subsequent to the date of execution of this Agreement: (A) committing or participating in an injurious act of, gross neglect or embezzlement against the Company; (B) committing or participating in any other injurious act or omission wantonly, willfully, recklessly or in a manner which was grossly negligent against the Company, monetarily or otherwise; (C) engaging in a criminal enterprise involving moral turpitude; or (D) the Employee being charged with or a conviction of an act or acts constituting a felony under the laws of the United States or any state thereof. Any other termination shall be deemed a termination “Other than for Cause.”

		d.	Termination by the Company Other than for Cause. The foregoing notwithstanding, the Company may terminate the Employee’s employment for whatever reason it deems appropriate: On the date of termination, the Employee’s unexercised vested Stock Options shall remain exercisable by the Employee through the term of such Options. On the date of termination, the Company shall pay to Employee the following benefits at the times specified below: (A) all Earned Compensation (to be paid on the date of termination), (B) an amount equal to all accrued and unpaid annual incentive bonuses relating to any prior years, if any, at the time of Employee’s termination of employment, (C) all Reimbursable Expenses, and, (D) a pro-rata portion of any annual incentive bonus becoming earned on performance for the fiscal year in which the date of termination occurs.

		e.	Voluntary Termination. In the event, the Employee terminates the Employee’s employment of the Employee’s own volition, on the date of termination the Employee’s unexercised vested Stock Options shall remain exercisable by the Employee through the term of such Options.

7.

Restrictive Covenant and Non-Disclosure of Information.

		a.	Restrictive Covenant. The Employee acknowledges and recognizes the highly competitive nature of the Company’s business and the goodwill, continued patronage, and specifically the names and addresses of the Company’s Clients (as hereinafter defined) constitute a substantial asset of the Company having been acquired through considerable time, money, and effort. Accordingly, in consideration of the execution of this Agreement, in the event the Employee’s employment is terminated by reason of disability pursuant to Section 6(b) or for Cause pursuant to Section 6(c) or if the Employee voluntarily terminates this Agreement pursuant to Section 6(e), then the Employee agrees that during the Restricted Period and within the Restricted Area, the Employee will not, directly or indirectly, solicit, induce or influence any of the Company’s Clients which have a business relationship with the Company at the time during the Restricted Period to discontinue or reduce the extent of such relationship with the Company and shall not solicit any current employee of the Company to offer them employment away from the Company.

		b.	Non-Disclosure of Information. In the event Employee’s employment has been terminated, Employee agrees that, during the Restricted Period, Employee will not knowingly use or disclose any Proprietary Information of the Company for the Employee’s own purposes or for the benefit of any entity engaged in Competitive Business Activities. As used herein, the term “Proprietary Information” shall mean trade secrets or confidential proprietary information of the Company which are material to the conduct of the business of the Company. No information can be considered Proprietary Information unless the same is a unique process or method material to the conduct of the Company’s business, or is a customer list or similar list of persons engaged in business activities with the Company, or if the same is otherwise in the public domain or is required to be disclosed by order of any court or by reason of any statute, law, rule, regulation, ordinance or other governmental requirements. Employee further agrees that in the event his employment is terminated all Documents in his possession at the time of his termination shall be returned to the Company at the Company’s principal place of business.

		c.	Documents. “Documents” shall mean all original written, recorded, or graphic matters whatsoever, and any and all copies thereof, including, but not limited to: papers; books; records; tangible things; correspondence; communications; telex messages; memoranda; work papers; reports; affidavits; statements; summaries; analyses; evaluations; client records and information; agreements; agendas; advertisements; instructions; charges; manuals; brochures; publications; directories; industry lists; schedules; price lists; client lists; statistical records; training manuals; computer printouts; books of account, records and invoices reflecting business operations; all things similar to any of the foregoing however denominated. In all cases where originals are not available, the term “Documents” shall also mean identical copies of original documents or non-identical copies thereof.

		d.	Company’s Clients. The “Company’s Clients” shall be deemed to be any partnerships, corporations, professional associations or other business organizations with whom the Company has conducted business.

		e.	Restrictive Period. The “Restrictive Period” shall be deemed to be five (5) years following termination of the Employee’s employment with the Company.

		f.	Restricted Area. The “Restricted Area” shall be within a three hundred (300) mile radius of the Company’s principal office at the time of termination.

		g.	Competitive Business Activities. The term “Competitive Business Activities” as used herein shall be deemed to mean the business of the Company at the time of termination.

		h.	Covenants as Essential Elements of this Agreement. It is understood by and between the parties hereto that the foregoing covenants contained in Sections 7(a) and (b) are essential elements of this Agreement, and that but for the agreement by the Employee to comply with such covenants, the Company would not have agreed to enter into this Agreement. Such covenants by the Employee shall be construed to be agreements independent of any other provisions of this Agreement. The existence of any other claim or cause of action, whether predicated on any other provision in this Agreement, or otherwise, because of the relationship between the parties shall not constitute a defense to the enforcement of such covenants against the Employee.

		i.	Survival After Termination of Agreement. Notwithstanding anything to the contrary contained in this Agreement, the covenants in Sections 7(a) and (b) shall survive the termination of this Agreement and the Employee’s employment with the Company.

		j.	Remedies.

		i.	The Employee acknowledges and agrees that the Company’s remedy at law for a breach or threatened breach of any of the provisions of Section 7(a) or (b) herein would be inadequate and a breach thereof will cause irreparable harm to the Company. In recognition of this fact, in the event of a breach by the Employee of any of the provisions of Section 7(a) or (b), the Employee agrees that, in addition to any remedy at law available to the Company, including, but not limited to monetary damages, all rights of the Employee to payment or otherwise under this Agreement and all amounts then or thereafter due to the Employee from the Company under this Agreement may be terminated and the Company, without posting any bond, shall be entitled to obtain, and the Employee agrees not to oppose the Company’s request for equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available to the Company.

		ii.	The Employee acknowledges that the granting of a temporary injunction, temporary restraining order, or permanent injunction merely prohibiting the use of Proprietary Information would not be an adequate remedy upon breach or threatened breach of Section 7(a) or (b) and consequently agrees, upon proof of any such breach, to the granting of injunctive relief prohibiting any form of competition with the Company. Nothing contained herein shall be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened breach.

	8.	Indemnification. The Employee shall continue to be covered by the Certificate of Incorporation and/or the Bylaws of the Company with respect to matters occurring on or prior to the date of termination of the Employee’s employment with the Company, subject to all the provisions of Delaware and Federal law and the Certificate of Incorporation and Bylaws of the Company then in effect. Such reasonable expenses, including attorneys’ fees, that may be covered by the Certificate of Incorporation and/or Bylaws of the Company shall be paid by the Company on a current basis in accordance with such provision, the Company’s Certificate of Incorporation, and Delaware law. To the extent that any such payments by the Company pursuant to the Company’s Certificate of Incorporation and/or Bylaws may be subject to repayment by the Employee pursuant to the provisions of the Company’s Certificate of Incorporation or Bylaws, or pursuant to Delaware or Federal law, such repayment shall be due and payable by the Employee to the Company within three (3) months after the termination of all proceedings, if any, which relate to such repayment and to the Company’s affairs for the period prior to the date of termination of the Employee’s employment with the Company and as to which Employee has been covered by such applicable provisions.

	9.	Background. Jupiter Wellness understands the importance of creating a safe and secure work environment for all employees. As such, the Company reserves the right to conduct background investigations and/or reference checks on all potential employees. Please note that any job offer extended by the Company is contingent upon the successful completion of such checks.

	10.	Policies. Jupiter Wellness employees are expected to follow the company’s rules and standards to create a safe and respectful workplace for everyone. To ensure compliance with these standards, employees will receive a copy of the Jupiter Wellness Employee Handbook, along with other relevant company policies, such as Regulation FD and Insider Trading Policies. The employee acknowledges that the terms of this contract are subject to and incorporate the policies and procedures set forth in the company’s employee handbook and any other applicable policies, which the employee agrees to review and abide by. The contract will not become effective until the employee signs and acknowledges receipt of the employee handbook and any other applicable policies.

	11.	Withholding. Anything to the contrary notwithstanding, all payments required to be made by the Company hereunder to the Employee or the Employee’s estate or beneficiaries shall be subject to the withholding of such amounts, if any, relating to tax and other payroll deductions as the Company may reasonably determine it should withhold pursuant to any applicable law or regulation. In lieu of withholding such amounts, the Company may accept other arrangements pursuant to which it is satisfied that such tax and other payroll obligations will be satisfied in a manner complying with applicable law or regulation.

	12.	Notices. Any notice required or permitted to be given under the terms of this Agreement shall be sufficient if in writing and if sent postage prepaid by registered or certified mail, return receipt requested; by overnight delivery; by courier; or by confirmed telecopy, in the case of the Employee to the Employee’s last place of business or residence as shown on the records of the Company, or in the case of the Company to its principal office as set forth in the first paragraph of this Agreement, or at such other place as it may designate.

	13.	Waiver. Unless agreed in writing, the failure of either party, at any time, to require performance by the other of any provisions hereunder shall not affect its right thereafter to enforce the same, nor shall a waiver by either party of any breach of any provision hereof be taken or held to be a waiver of any other preceding or succeeding breach of any term or provision of this Agreement. No extension of time for the performance of any obligation or act shall be deemed to be an extension of time for the performance of any other obligation or act hereunder.

	14.	Completeness and Modification. This Agreement constitutes the entire understanding between the parties hereto superseding all prior and contemporaneous agreements or understandings among the parties hereto concerning the Employment Agreement. This Agreement may be amended, modified, superseded, or canceled, and any of the terms, covenants, representations, warranties, or conditions hereof may be waived, only by a written instrument executed by the parties or, in the case of a waiver, by the party to be charged.

	15.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute but one agreement.

	16.	Binding Effect/Assignment. This Agreement shall be binding upon the parties hereto, their heirs, legal representatives, successors, and assigns. This Agreement shall not be assignable by the Employee but shall be assignable by the Company in connection with the sale, transfer, or other disposition of its business or to any of the Company’s affiliates controlled by or under common control with the Company.

	17.	Governing Law. This Agreement shall become valid when executed and accepted by Company. The parties agree that it shall be deemed made and entered into in the State of Florida and shall be governed and construed under and in accordance with the laws of the State of Florida. Anything in this Agreement to the contrary notwithstanding, the Employee shall conduct the Employee’s business in a lawful manner and faithfully comply with applicable laws or regulations of the state, city, or other political subdivision in which the Employee is located.

	18.	Further Assurances. All parties hereto shall execute and deliver such other instruments and do such other acts as may be necessary to carry out the intent and purposes of this Agreement.

	19.	Headings. The headings of the sections are for convenience only and shall not control or affect the meaning or construction or limit the scope or intent of any of the provisions of this Agreement.

	20.	Survival. Any termination of this Agreement shall not, however, affect the ongoing provisions of this Agreement which shall survive such termination in accordance with their terms.

	21.	Severability. The invalidity or unenforceability, in whole or in part, of any covenant, promise or undertaking, or any section, subsection, paragraph, sentence, clause, phrase, or word or of any provision of this Agreement shall not affect the validity or enforceability of the remaining portions thereof.

	22.	Enforcement. Should it become necessary for any party to institute legal action to enforce the terms and conditions of this Agreement, the successful party will be awarded reasonable attorney’s fees at all trial and appellate levels, expenses, and costs.

	23.	Venue. The Company and the Executive acknowledge and agree that the 15^th Judicial Circuit of Florida shall be the venue and exclusive proper forum in which to adjudicate any case or controversy arising either, directly or indirectly, under or in connection with this Agreement and the parties further agree that, in the event of litigation arising out of or in connection with this Agreement in these courts, they will not contest or challenge the jurisdiction or venue of these courts.

	24.	Construction. This Agreement shall be construed within the fair meaning of each of its terms and not against the party drafting the document.

	25.	Superseding Agreement. This Agreement supersedes all prior or contemporaneous agreements, whether written or oral, and constitutes the entire understanding between the parties. Any changes to this Agreement must be in writing and signed by both parties. If there is any conflict between this Agreement and any other document or agreement related to the subject matter, this Agreement shall prevail.

	26.	Approval of Named Officers. Notwithstanding any provision to the contrary, any compensation, incentive, or benefit arrangement for Named Officers of the company shall be deemed effective only upon the express approval of the Board of Directors, following a recommendation from the Compensation Committee.

IN WITNESS WHEREOF, the parties have executed this Agreement as of date set forth in the first paragraph of this Agreement.

	THE COMPANY

	JUPITER WELLNESS, INC.

	By:	/s/
		Brian John, CEO

	THE EMPLOYEE

		/s/

APPENDIX A
EQUITY COMPENSATION DETAILS

This appendix contains additional information about the Employee’s compensation through the issuance of either stock options or restricted stock. Please refer to this appendix for a detailed description of the grant date, vesting schedule, and strike price for these equity awards.

Jupiter Wellness, Inc. hereby grants the Employee stock options to purchase up to 100,000 shares of our common stock (the “Stock Options”). These Stock Options are subject to the terms and conditions set forth in the Company’s 2022 Omnibus Equity Incentive Plan (the “Plan”).

Covered Shares:		100,000 shares of common stock, par value $0.001 per share.

Date of Grant:		The “Date of Grant” for the Stock Options is July 10^th, 2023.

Exercise Price:		The purchase price for these shares will be the closing market price of the Company’s stock on the Date of Grant.

Vesting Schedule:		You may exercise your Stock Options after they become “vested.” Vesting is subject to continued employment with Jupiter Wellness, Inc. after the Date of the Grant.

Vesting Date		Number of Purchasable Shares		Total Number of Purchasable Shares
July 10, 2023		8337		8337
October 10, 2023		8333		16670
January 10, 2024		8333		25003
April 10, 2024		8333		33336
July 10, 2024		8333		41669
October 10, 2024		8333		50002
January 10, 2025		8333		58335
April 10, 2025		8333		66668
July 10, 2025		8333		75001
October 10, 2025		8333		83334
January 10, 2026		8333		91667
April 10, 2026		8333		100000

Termination:		Subject to the terms of the Plan, the vested portion of the Stock Options will remain exercisable for 90 days after the date of employment termination.

ISOs:		These Stock Options are “incentive stock options” under federal tax laws.

Expiration Date:		If not previously exercised or forfeited, the Stock Options expire on July 10^th, 2028.

EX-99.1 4 ex99-1.htm

Exhibit 99.1

Key GBB Drink Lab Executives to Join Jupiter Wellness’ C-Suite. Josh Wagner and David Sandler Will Bring Their Experience and Knowledge to Jupiter Wellness as it Deploys a Multi-Channel Strategy to Bring Safety Shot to Market

JUPITER, FL – July 11, 2023 — Jupiter Wellness, Inc. (Nasdaq: JUPW), a diversified company that supports health and wellness, today announced that along with the Asset Purchase Agreement for the Company’s purchased patents and provisional patents, two GBB Drink Lab executives will join Jupiter Wellness’ C-suite: Josh Wagner and David Sandler.

Josh Wagner, will serve as Jupiter Wellness’ Chief Revenue Officer. Josh is the former U.S. Director of Sales for Anheuser Busch, leading a $12 billion business with a 72 person sales team to their best performance since 2009. Josh created and launched multiple innovative brands from scratch to shelf.

David Sandler, will serve as the Company’s Chief Operating Officer. With more than 30 years experience in the nutrition and health industry, David is the former COO and CSO of several supplement brands that exceeded $75 million in revenue. With a focus on EBIDTA and bottom-line profits, David is one of the industry’s top R&D experts and a leader in creating best in class products from ideation and concept to full commercialization.

“We welcome Josh and David on board as we prepare to aggressively launch a product that has shown great early results. We have also had a few people that reported feeling more clear-minded and focused after consuming 4oz of the drink without the presence of alcohol. I look forward to performing more trials on the drink to show its true potential Jupiter Wellness CEO Brian John stated.

“In my 30 years in the industry, this is the biggest disruption to hit the drink market. Once in a while a true unicorn comes along that not only defines but recreates a new standard for a category, and this is it. Until now, nobody has been able to improve function, improve sobriety, improve BAC, reduce hangovers and help people feel better faster from the effects of alcohol. Safety Shot simply changes the game completely.” COO David Sadler Stated.

The global hangover cure products market size is expected to reach USD 4.67 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 14.6% from 2021 to 2028.

1

GBB Drink Lab started with a vision of making a positive impact by offering practical, evidence-based solutions to reducing Blood Alcohol Content. The company’s product has been meticulously crafted to optimize your ability to sober up enabling you to escape an inebriated state. GBB Drink Lab’s leadership team includes accomplished serial entrepreneurs, a former senior executive from one of the world’s largest beverage companies, and an industry-leading expert in flavoring science and product formulation.

Jupiter Wellness, Inc., a wellness company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sells its products through third-party physical retail stores and partners. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.

Forward Looking Statements

This communication contains forward-looking statements regarding Jupiter Wellness, including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company’s current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond Jupiter Wellness’ control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Jupiter Wellness and, including those described from time to time under the caption “Risk Factors” and elsewhere in Jupiter Wellness’ Securities and Exchange Commission (SEC) filings and reports, including Jupiter Wellness’ Annual Report on Form 10-K for the year ended December 31, 2023 and future filings and reports by Jupiter Wellness. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Jupiter Wellness on its website or otherwise. Jupiter Wellness undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Jupiter Wellness Media Contact:

Phone: 561-244-7100

Email: info@JupiterWellness.com

###

2

GRAPHIC 5 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end GRAPHIC 6 ex99-1_002.jpg begin 644 ex99-1_002.jpg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end EX-101.SCH 7 jupw-20230707.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 8 jupw-20230707_def.xml XBRL DEFINITION FILE EX-101.LAB 9 jupw-20230707_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Warrants, each exercisable for one share of Common Stock at $8.50 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 10 jupw-20230707_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover	Jul. 07, 2023
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 07, 2023
Entity File Number	001-39569
Entity Registrant Name	JUPITER WELLNESS, INC.
Entity Central Index Key	0001760903
Entity Tax Identification Number	83-2455880
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1061 E. Indiantown Rd.
Entity Address, Address Line Two	Ste. 110
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33477
City Area Code	(561)
Local Phone Number	462-2700
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Information, Former Legal or Registered Name	Not Applicable
Common Stock [Member]
Title of 12(b) Security	Common Stock
Trading Symbol	JUPW
Security Exchange Name	NASDAQ
Warrants, each exercisable for one share of Common Stock at $8.50 per share
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock at $8.50 per share
Trading Symbol	JUPWW
Security Exchange Name	NASDAQ

XML 12 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001760903 2023-07-07 2023-07-07 0001760903 us-gaap:CommonStockMember 2023-07-07 2023-07-07 0001760903 JUPW:WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember 2023-07-07 2023-07-07 iso4217:USD shares iso4217:USD shares 0001760903 false 8-K 2023-07-07 JUPITER WELLNESS, INC. DE 001-39569 83-2455880 1061 E. Indiantown Rd. Ste. 110 Jupiter FL 33477 (561) 462-2700 Not Applicable false false false false Common Stock JUPW NASDAQ Warrants, each exercisable for one share of Common Stock at $8.50 per share JUPWW NASDAQ true false EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 25 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://jupiterwellness.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ex10-2.htm ex99-1.htm jupw-20230707.xsd jupw-20230707_def.xml jupw-20230707_lab.xml jupw-20230707_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 28 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "jupw-20230707_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "jupw-20230707_lab.xml" ] }, "presentationLink": { "local": [ "jupw-20230707_pre.xml" ] }, "schema": { "local": [ "jupw-20230707.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 1, "memberStandard": 1, "nsprefix": "JUPW", "nsuri": "http://jupiterwellness.com/20230707", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-07-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://jupiterwellness.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-07-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "JUPW_WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each exercisable for one share of Common Stock at $8.50 per share" } } }, "localname": "WarrantsEachExercisableForOneShareOfCommonStockAt8.50PerShareMember", "nsuri": "http://jupiterwellness.com/20230707", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://jupiterwellness.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001493152-23-024172-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-024172-xbrl.zip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end